Search results for "Lip"

showing 10 items of 8306 documents

From Menace to Marvel

2009

Diabetes mellitus is a major risk factor for cardiovascular disease, and its prevalence is suspected to further increase in the coming years in the Western hemisphere and also in countries with emerging economies, like India, China, and Brazil. Together with the increasing prevalence of obesity and metabolic syndrome and the subsequent development of arterial hypertension, the epidemic of adiposity and diabetes mellitus may eat up most of the improvement of cardiovascular outcomes that we have seen within the last decades.1 The risk of atherosclerosis is inversely related to circulating levels of high-density lipoprotein (HDL) cholesterol. Results from the Framingham Study demonstrated that…

medicine.medical_specialtyApolipoprotein BbiologyCholesterolbusiness.industryReverse cholesterol transportTorcetrapibnutritional and metabolic diseasesmedicine.diseaseAngiotensin IIchemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineInternal Medicinemedicinebiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessLipoproteinHypertension
researchProduct

Estudio de los valores plasmáticos de Lp(a) en el defecto familiar de unión de la apo B 100 en una población mediterránea del sur de Europa

2004

Aims: 1) to study lipoprotein (a) (Lp(a)) plasma values in subjects with familial ligand-defective apo B 100 (FDB). Methods: We studied 19 heterozygous FDB subjects (8 males) from 12 families, carriers of R3500Q mutation on apo B gene and 90 controls (34 males). The genetic diagnosis was established with PCR-SSCP analysis and automatic sequencing. In all subjects plasma lipids, apoli-poprotein B and Lp(a) levels were determined with standard procedures. Results: Subjects carriers of R3500Q mutation on apo B gene have significantly higher plasma Lp(a) and log transformed Lp(a) values and prevalence of Lp(a) > 30 cut point for coronary heart disease than controls. Conclusions: Subjects with F…

medicine.medical_specialtyApolipoprotein Bbiologybusiness.industryCoronary heart diseaseEndocrinologyInternal medicinePlasma lipidsInternal Medicinebiology.proteinmedicineGenetic diagnosisbusinessLipoproteinAnales de Medicina Interna
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Proteome alterations in aqueous humour of primary open angle glaucoma patients.

2019

Aim To unravel the primary open angle glaucoma (POAG) related proteomic changes in aqueous humour (AH). Methods Totally 35 patients listed for cataract surgery (controls: n=12, age: 67.4±13.6y) or trabeculectomy for POAG (n=23, age: 72.5±8.3y) were included. AH samples of those patients were obtained during cataract surgery or trabeculectomy. AH samples were subsequently pooled into the experimental groups under equal contribution in terms of protein amount of each individual patient. Protein samples were analyzed by a linear trap quadrupol Orbitrap Mass Spectrometry device with an upstream liquid chromatography system. The obtained raw data were analyzed using the Maxquant proteome softwar…

medicine.medical_specialtyApolipoprotein DOpen angle glaucomagenetic structuresmedicine.medical_treatmentGlaucomaproteomicslcsh:OphthalmologyOphthalmologyMedicineTrabeculectomywnt signaling pathwaybusiness.industryAqueous humourBrief ReportCataract surgerymedicine.diseaseFold changeprimary open angle glaucomaeye diseasesOphthalmologylcsh:RE1-994Proteomesense organsbusinessaqueous humorInternational journal of ophthalmology
researchProduct

Mild cognitive impairment: A systematic review

2007

MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI ( aMCI) characterized by reduced memory, and non- amnestic MCI ( naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous - including vascular dementia, frontotemporal dementia or dementia with Lewy bodies- but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classifi…

medicine.medical_specialtyApolipoprotein E4Neuropsychological TestsSeverity of Illness Indexbehavioral disciplines and activitiesPhysical medicine and rehabilitationNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Risk Factorsmental disordersEpidemiologySeverity of illnessmedicineHumansDementiaVascular dementiaapolipoprotein EAlzheimer disease; apolipoprotein E; biomarkers; diagnosis; mild congnitive impairmentMemory Disordersbusiness.industryDementia VascularGeneral NeuroscienceBrainCognitionGeneral Medicinemedicine.diseaseMagnetic Resonance Imagingmild congnitive impairmentdiagnosiPsychiatry and Mental healthClinical PsychologyEtiologybiomarkerSettore MED/26 - NeurologiaRadiopharmaceuticalsGeriatrics and GerontologyCognition DisordersbusinessFrontotemporal dementia
researchProduct

Physiological and Nutritional Roles of PPAR across Species.

2013

There has been a tremendous amount of information produced on peroxisome proliferator-activated receptors (PPARs). The interest in PPARs was originally driven largely by their role in hypolipidemia and hepatocarcinogenesis, but it soon became evident that they played important roles in the metabolic syndrome and overall health of organisms including regeneration of tissues, differentiation, insulin signaling, overall lipid metabolism, and immune response (reviewed in [1–7]). From a nutritional standpoint, the PPARs are of extreme importance because of their ability to bind and be activated by long-chain fatty acids and their metabolites. Therefore, the PPARs are recognized as ideal candidat…

medicine.medical_specialtyArticle SubjectAnimal food[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Peroxisome proliferator-activated receptorAdipose tissueContext (language use)White adipose tissueBiologyBioinformaticsEnergy homeostasis03 medical and health sciencesInternal medicineDrug Discoverymedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Pharmacology (medical)[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biologylcsh:QH301-705.5[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyComputingMilieux_MISCELLANEOUS030304 developmental biology2. Zero hungerchemistry.chemical_classification[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism0303 health sciences[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]0402 animal and dairy scienceLipid metabolism04 agricultural and veterinary sciences[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism040201 dairy & animal scienceNutrigenomicsEndocrinologyEditoriallcsh:Biology (General)chemistry
researchProduct

PPAR in Cardiovascular Disorders

2016

Peroxisome proliferation-activated receptors (PPARs) are ligand-inducible transcription factors that, upon binding their ligands, translocate into the nucleus, where they regulate transcription of numerous genes that have the peroxisome proliferator response element (PPRE) in the promoter region [1]. In humans, there are 3 PPAR isoforms: PPAR-α, PPAR-β/δ, and PPAR-γ. The isoforms have partially overlapping spectra of activity and are differently expressed in organs and tissues [2]. PPAR-α is expressed mostly in tissues characterized by high catabolic activity, including skeletal muscle, liver, proximal tubular cells in kidneys, and brown fat. This PPAR isoform regulates components of β-oxid…

medicine.medical_specialtyArticle SubjectPeroxisome proliferator-activated receptor030209 endocrinology & metabolism030204 cardiovascular system & hematologyBiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationInternal medicineDrug DiscoverymedicineGlucose homeostasisPharmacology (medical)Beta oxidationlcsh:QH301-705.5chemistry.chemical_classificationFatty acid metabolismLipid metabolismPeroxisomeEndocrinologyEditorialchemistrylcsh:Biology (General)Rosiglitazonemedicine.drugPPAR Research
researchProduct

The Influence of Treated and Untreated Subclinical Hypothyroidism on Metabolic Profile in Women with Polycystic Ovary Syndrome.

2021

Background. Polycystic ovary syndrome (PCOS) and hypothyroidism are the most common endocrinological disorders among women of reproductive age. Since hypothyroidism occurs more frequently in PCOS patients, it is vital to explain its clinical impact. Aim. To evaluate the impact of subclinical hypothyroidism (SCH) and its treatment on the metabolic profile of patients with PCOS. Methods. 190 women with PCOS phenotype A were enrolled in the case-control study. They were divided into three groups: 38 women with PCOS and subclinical hypothyroidism, 76 women with PCOS and SCH under thyroid replacement therapy, and 76 women with PCOS and normal thyroid function (control group). Serum lipids, fasti…

medicine.medical_specialtyArticle Subjectendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentBlood lipidsDiseases of the endocrine glands. Clinical endocrinologychemistry.chemical_compoundEndocrinologyInsulin resistanceInternal medicineMedicineSubclinical infectionEndocrine and Autonomic Systemsbusiness.industryCholesterolInsulinThyroidnutritional and metabolic diseasesRC648-665medicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologymedicine.anatomical_structurechemistryThyroid functionbusinessResearch ArticleInternational journal of endocrinology
researchProduct

Non-glycemic effects of pioglitazone and incretin-based therapies.

2013

Atherosclerosis and cardiovascular events are highly prevalent and represent the major cause of mortality in patients with type 2 diabetes. Therefore, there is significant interest in the non-glycemic properties of anti-diabetic agents, particularly on those that are effective on cardiovascular risk factors. Thiazolidinediones and incretin-based therapies (IBTs) represent some of the most recent treatment options approved for the management of type 2 diabetes; these agents have shown important glycemic effects, as well as a number of non-glycemic effects. The latter include those on body weight, inflammation, hypertension and dyslipidemia, thus impacting the different components of the meta…

medicine.medical_specialtyAtherosclerosis cardiovascular events type 2 diabetes pioglitazone incretin-based therapiesClinical BiochemistryMEDLINEIncretinType 2 diabetesPharmacologyIncretinsDrug DiscoverymedicineHumansHypoglycemic AgentsIn patientIntensive care medicineGlycemicDyslipidemiasPharmacologyPioglitazonebusiness.industryBody Weightmedicine.diseaseCardiovascular DiseasesMolecular MedicineThiazolidinedionesMetabolic syndromebusinessPioglitazoneDyslipidemiamedicine.drug
researchProduct

Chatting Between the Brain and White Adipose Tissues

2012

Over the past decades, numerous papers have been published demonstrating the importance of the relationships between the brain and white adipose tissues in regard to body weight and metabolism regulation. Indeed the brain mainly via the sympathetic nervous system control body fat mass both by regulating adipocytes metabolism (lipolysis and lipogenesis), secretory activity (leptin and other adipokines) as well as development. In turn fat mass will send information to some brain areas via sensory nerves as well as via changes in metabolic and hormonal signals. Altogether these data are in support of a feedback loop between white adipose tissues and the brain. This crosstalk plays a major role…

medicine.medical_specialtyAutonomic nervous systemEndocrinologyInternal medicineLeptinLipogenesismedicineAdipokineLipolysisAdipose tissueWhite adipose tissueBiologyEnergy homeostasis
researchProduct